June 23rd 2025
A total of 13 drugs were granted recommendation for market authorization at EMA’s CHMP June 2025 meeting.
McNeil Voluntarily Recalls Infants' Tylenol Oral Suspension Product
February 23rd 2012On Feb. 17, 2012, McNeil Consumer Healthcare, a division of McNeil-PPC, a subsidiary of Johnson & Johnson, voluntarily recalled approximately 574,000 bottles of its OTC pain reliever and fever reducer Infants' Tylenol Oral Suspension, 1 oz. Grape. The voluntary recall was initiated after consumers complained of having difficulty using the SimpleMeasure dosing system.
FDA Issues Warning Letters for Three Merck KGaA Plants
February 23rd 2012On Feb. 21, 2011, FDA posted a copy of a Warning Letter that was sent to the chairman of the executive board of Merck KGaA on Dec. 15, 2011, regarding cGMP violations identified at three of its European facilities: MS-Corsier-sur-Vevey, MS-Aubonne, and MS-Tiburtina.
FDA Releases Draft Guidance on Monitoring Crude Heparin for Quality
February 16th 2012FDA has released a draft guidance for API manufacturers in response to a 2008 incident in which heparin sourced from China was adulterated with oversulfated chondroitin sulfate, causing serious adverse reactions in patients.
FDA Files Consent Decree Against Ranbaxy
February 2nd 2012The US Department of Justice, on behalf of FDA, filed a consent decree of permanent injunction against the generic-drug manufacturer Ranbaxy in the US District Court of Maryland. The decree was filed on Jan. 25, 2012, and is subject to court approval.
USP Announces Proposed Standard for Supply-Chain Integrity
January 12th 2012The US Pharmacopeia announced a draft standard containing best practices for ensuring that drugs can be traced to their original manufacturer, are not counterfeited or adulterated, and can be transported to their intended destination without compromising quality.